ARHGAP27P2

Across TCGA pan-cancer cohorts, ARHGAP27P2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARHGAP27P2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ARHGAP27P2 RNA is repressed in tumor relative to normal tissue. In most cancer types ARHGAP27P2 is over-expressed in tumor, although a few such as BLCA and BRCA show the opposite, repressed pattern.

BLCA, BRCA, and LUSC are the cancer types where ARHGAP27P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGAP27P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	−0.265	<.001	11	view →
BRCA	All	II,III,IV	−0.192	<.001	6	view →
LUSC	Male	II,III,IV	+0.196	.011	4	view →
PRAD	All	All	−0.142	.007	2	view →
STAD	Female	III,IV	+0.610	.001	1	view →
CHOL	Female	All	+0.460	.045	1	view →
HNSC	All	All	+0.206	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARHGAP27P2–BLCA

Open the BLCA breakdown →